AKAjay Kumar

Ajay Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajay Kumar has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive PASS-powered elucidation of phytoconstituent therapeutic profiles for advanced psoriasis intervention strategies

    by Ajay Kumar, Vinayak Bhushan, Rakesh K Sindhu

    Psoriasis is a chronic inflammatory skin disease marked by immune dysregulation, leading to rapid skin cell turnover and formation of thick, red, scaly plaques, mainly on the scalp, elbows, knees, and lower back. These plaques cause itching, pain, and significant quality-of-life impairment. The most common form, plaque psoriasis, accounts for 80–90% of cases. Although the Th17/IL-23 pathway is known to play a key role in disease pathogenesis, variability in disease progression and response to biologic therapies underlines the need for more personalized treatments. Recently, natural products have gained interest for their anti-inflammatory and immunomodulatory effects in psoriasis management. Compounds like curcumin, quercetin, and naringin have shown beneficial modulation of key inflammatory pathways. Pharmacological studies using computational tools (PASS software) have predicted bioactivities of plant-derived compounds such as quercetin, curcumin, kaempferol, stigmasterol, taraxerol, aloesin, emodin, and mukulol against biological targets linked to psoriasis—including tumor necrosis factor-α, antioxidant enzymes, lipoxygenase, cytochrome P450, and Janus kinase. This integrated investigation supports the therapeutic promise of these natural compounds for psoriasis, suggesting potential for developing more effective and targeted treatments.

  • Open Access

    Design, optimization, and characterization of curcumin-loaded proniosomal vesicular systems as a novel phytopharmaceutical delivery strategy for psoriasis management

    by Ajay Kumar, Rakesh K Sindhu, Satyender Kumar, Mohammad Rashid Khan

    Herbal therapeutics such as curcumin have potent anti-inflammatory and antioxidant potential but face challenges of low solubility, poor bioavailability, and instability. Proniosomes, surfactant-coated dry vesicular carriers, offer enhanced stability, scalability, and bioavailability, making them suitable for delivering insoluble herbal actives through topical applications. This study was designed to develop and optimize curcumin-loaded Proniosomes using Box-Behnken Design (BBD) to improve physicochemical features for psoriasis management. Proniosomes were prepared by antisolvent precipitation using Span 80, soya lecithin, and cholesterol. A three-factor, three-level BBD was applied to evaluate the effect of Span (X₁), lecithin (X₂), and cholesterol (X₃) on critical quality attributes: particle size (Y₁), zeta potential (Y₂), and PDI (Y₃). Seventeen runs were performed and statistically analyzed using ANOVA, Pearson’s correlation, and lack-of-fit testing. Entrapment efficiency and in vitro drug release were further measured. Formulations showed particle sizes of 143–366 nm, zeta potential of 14–32 mV, and PDI of 0.045–0.53. The optimized batch exhibited ~206 nm particle size, ~24 mV zeta potential, and 0.22 PDI. Entrapment efficiency reached ~84%, while drug release was sustained over 24 h, with ~96.64% cumulative release at 48 h compared to ~25.5% for pure curcumin. Enhanced release was attributed to the amphiphilic surfactants forming stable bilayered vesicles, and cholesterol providing structural integrity for controlled release. In conclusion, optimized curcumin Proniosomes established high stability, scalability, entrapment, and sustained release, providing a promising topical delivery platform for effective psoriasis management.

  • Open Access

    Proniosome-based smart delivery systems for Psoriasis-targeted bioactive therapy

    by Ajay Kumar, Shuchi Goyal, Sahil Kumar, Sumitra Singh, Rakesh K Sindhu

    The growth in the field of nanotechnology has brought forth the growth of several breakthroughs that have prompted formulation of new solutions. Nanocarriers occur as minute encapsulating agents of the drug molecules thus stabilizing and improving the therapeutic effects of the encapsulated drugs. The self-assembly characteristic of proniosomes reduces the challenges that are normally encountered in liposomal and niosomal drug delivery systems. Due to their ability to self-assemble, proniosomes are the focus of constant investigating in the field of drug delivery systems. However, there is still great potential for future research concerning the development of new carrier materials for proniosomal formulation. Versatile proniosome-derived niosomes prove to be a reliable and relatively inexpensive system for drug delivery that possesses a number of significant advantages over conventional vesicular and traditional pharmaceutical formulations. Bioactive agents and recent advancements along with ethical considerations in the formation of proniosomes for psoriasis is further discussed in this review article. Novel hypotheses estimate repeated improvements in oral biopharmacokinetics, preferential drug targeting to the site of action, postponing the systemic biotransformation of the drug, which would lead to minimizing toxicity.